Two pharmaceuticals tiddlers that could beat the best stocks

Could these gems from the pharmaceuticals sector bring you big profits?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There are few things growth investors likes more than checking the news and seeing one of their shares climbing.

FDA approval

That’s what awaited Beximco Pharmaceuticals (LSE: BXP) shareholders this morning, with their shares up 20% in early trading to 55p. But that’s only part of the growth story — Beximco shares are up 175% over the past 12 months, and have risen nearly fivefold in the past five years.

So what’s behind it — some revolutionary new discoveries? Actually, no, the Bangladesh-based company does something simpler but profitable — it manufactures generic pharmaceuticals products, which sell in great quantity and at much lower prices than their branded counterparts, and are a boon to much of the developing world.

It’s what happens to a lot of pioneering products invented by the likes of GlaxoSmithKline and AstraZeneca when their patents expire, which is something both giants have been suffering from in recent years, and the drugs end up being made by companies like Beximco and sold cheaply.

Today’s big share price gain is a result of the company receiving a second product approval from America’s FDA, this time for Sotalol Hydrochloride, a generic version of the cardiovascular drug Betapace — and cardiovascular medicine is big business in overfed Western countries. The product should launch in early 2017.

There are no forecasts for Beximco, but even after today’s rise they’re still only on a trailing P/E of 11 based on December 2015 figures. And with a maiden dividend last year yielding 3.9%, we could be looking at one of tomorrow’s cash cows.

A growth star

Back in 2011, speciality drugs and pharmaceutical services firm Clinigen (LSE: CLIN) was top of the Sunday Times Fast Track 100 list, which ranks the country’s fastest growing privately held companies. Clinigen went on to float on the London Stock Exchange in 2012 and since then its track record has been stellar, with a quadrupling of the share price to 742p.

Today the company announced an extension of its partnership with healthcare company BTG, with a new agreement “to manage BTG’s critical care portfolio across the whole of Europe and now into new territories in Asia.

Chief commercial officer Steve Glass enthused that the deal “demonstrates the value of our unique, synergistic businesses, which enables us to provide safe and ethical access to a medicine throughout its lifecycle – from development to approval, to launch and beyond.

But after their meteoric rise, are Clinigen shares still worth buying? Since that maiden set of results in 2012, we’ve seen earnings per share soar by 160%, and there’s a further 18% currently being forecast for the year to June 2017. If anything, that seems conservative to me, especially in the light of 2016 results released last month.

Revenue for the year rose by 84%, with adjusted EBITDA up 73%. There was plenty of cash coming in too, with cash flow up 213%, and that fed through to a dividend rise of 18%. Dividend yields are still modest at under 1%, but a progressive policy is lifting them well ahead of inflation every year. There’s a further 19% hike on the cards for the current year, and I see terrific potential for long-term dividend growth here.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca, BTG, and Clinigen. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Happy parents playing with little kids riding in box
Investing Articles

2 FTSE 250 dividend growth stocks I’m considering for passive income

Paul Summers thinks the best dividend stocks to buy are those that consistently return more money to investors every year.

Read more »

Investing Articles

The Compass Group share price looks ready for growth after positive 2024 results

The Compass Group share price is up 4% today following positive full-year results. Our writer considers its prospects in 2025…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

How I plan to build an £86k yearly second income in the stock market

Is it realistic to aim for a substantial future second income by investing in high-quality shares? This writer firmly believes…

Read more »

Investing Articles

Here’s the Vodafone share price forecast up to 2027

Can anything stop the Vodafone share price slide? It's still early days for the company's turnaround plan, so we might…

Read more »

Investing Articles

Down 37%, here’s one of my favourite FTSE 100 bargain shares to consider

This FTSE 100 retailer's shares have collapsed in 2024. Despite tough trading conditions, is now the time to consider buying…

Read more »

Investing Articles

Which do I like best today, Nvidia or Tesla stock?

EV maker Tesla stock is on the up, while Nvidia growth is softening a bit. But they're both in the…

Read more »

Investing Articles

After jumping 15%, my favourite FTSE 250 stock looks set for the premier league

Games Workshop stock recently reached an all-time high, placing it within touching distance of promotion from the FTSE 250.

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

1 top growth stock on my Christmas buy list!

Ben McPoland reveals one top-notch growth stock down 29% that he plans to stuff into his portfolio in time for…

Read more »